355 related articles for article (PubMed ID: 37239930)
1. Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.
Sarafanov AG
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239930
[TBL] [Abstract][Full Text] [Related]
2. Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A.
Konkle BA
Expert Rev Hematol; 2023; 16(8):567-573. PubMed ID: 37289594
[TBL] [Abstract][Full Text] [Related]
3. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories.
Pipe S; Sadeghi-Khomami A; Konkle BA; Kitchen S; Negrier C; Liu M; Santagostino E; Willemze A; Abad-Franch L; Knobe K; Seth Chhabra E
Haemophilia; 2024 Jan; 30(1):214-223. PubMed ID: 37902390
[TBL] [Abstract][Full Text] [Related]
4. Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A.
Abdelgawad HAH; Foster R; Otto M
Blood Rev; 2024 Mar; 64():101164. PubMed ID: 38216442
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor.
Elsheikh E; Lavin M; Heck LA; Larkin N; Mullaney B; Doherty D; Kennedy M; Keenan C; Guest T; O'Mahony B; Fazavana J; Fallon PG; Preston RJS; Gormley J; Ryan K; O'Connell NM; Singleton E; Byrne M; McGowan M; Roche S; Doyle M; Crowley MP; O'Shea SI; Reipert BM; Johnsen JM; Pipe SW; Di Paola J; Turecek PL; O'Donnell JS;
J Thromb Haemost; 2023 May; 21(5):1123-1134. PubMed ID: 36775768
[TBL] [Abstract][Full Text] [Related]
6. Efanesoctocog alfa elicits functional clot formation that is indistinguishable to that of recombinant factor VIII.
Demers M; Aleman MM; Kistanova E; Peters R; Salas J; Seth Chhabra E
J Thromb Haemost; 2022 Jul; 20(7):1674-1683. PubMed ID: 35466511
[TBL] [Abstract][Full Text] [Related]
7. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
[TBL] [Abstract][Full Text] [Related]
8. Biological mechanisms underlying inter-individual variation in factor VIII clearance in haemophilia.
Turecek PL; Johnsen JM; Pipe SW; O'Donnell JS;
Haemophilia; 2020 Jul; 26(4):575-583. PubMed ID: 32596930
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
Rakmanotham A; Moonla C; Sosothikul D
Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
[TBL] [Abstract][Full Text] [Related]
10. Perspective - The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021.
Di Minno A; Spadarella G; Esposito S; Mathew P; Di Minno G; Mannucci PM
Blood Rev; 2021 Nov; 50():100849. PubMed ID: 34024681
[TBL] [Abstract][Full Text] [Related]
11. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B.
Abraham S; Duncan EM
Methods Mol Biol; 2023; 2663():569-588. PubMed ID: 37204737
[TBL] [Abstract][Full Text] [Related]
12. Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life factor VIII replacement drugs: EudraVigilance data of 2021.
Abbattista M; Ciavarella A; Noone D; Peyvandi F
J Thromb Haemost; 2023 Mar; 21(3):546-552. PubMed ID: 36710195
[TBL] [Abstract][Full Text] [Related]
13. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
[TBL] [Abstract][Full Text] [Related]
14. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
[TBL] [Abstract][Full Text] [Related]
15. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
Srichumpuang C; Rakmanotham A; Moonla C; Sosothikul D
Orphanet J Rare Dis; 2024 Mar; 19(1):135. PubMed ID: 38532451
[TBL] [Abstract][Full Text] [Related]
16. Laboratory monitoring of new hemostatic agents for hemophilia.
Pruthi RK
Semin Hematol; 2016 Jan; 53(1):28-34. PubMed ID: 26805904
[TBL] [Abstract][Full Text] [Related]
17. Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.
Lissitchkov T; Willemze A; Katragadda S; Rice K; Poloskey S; Benson C
Blood Adv; 2022 Feb; 6(4):1089-1094. PubMed ID: 34794179
[TBL] [Abstract][Full Text] [Related]
18. Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays.
Peyvandi F; Kenet G; Pekrul I; Pruthi RK; Ramge P; Spannagl M
J Thromb Haemost; 2020 Jun; 18(6):1242-1255. PubMed ID: 32115865
[TBL] [Abstract][Full Text] [Related]
19. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
[TBL] [Abstract][Full Text] [Related]
20. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
